| Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the C … AR Lyon, S Dent, S Stanway, H Earl, C Brezden‐Masley, A Cohen‐Solal, ... European journal of heart failure 22 (11), 1945-1960, 2020 | 512 | 2020 |
| 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial HM Earl, L Hiller, AL Vallier, S Loi, K McAdam, L Hughes-Davies, ... The Lancet 393 (10191), 2599-2612, 2019 | 293 | 2019 |
| CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how? K Dickstein, C Normand, A Auricchio, N Bogale, JG Cleland, AK Gitt, ... European journal of heart failure 20 (6), 1039-1051, 2018 | 135 | 2018 |
| Management of cardiovascular risk in patients with multiple myeloma C Plummer, C Driessen, Z Szabo, MV Mateos Blood cancer journal 9 (3), 26, 2019 | 90 | 2019 |
| Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report AFC Okines, RE Langley, LC Thompson, SP Stenning, L Stevenson, ... Annals of oncology 24 (3), 702-709, 2013 | 85 | 2013 |
| ESC core curriculum for the cardiologist FC Tanner, N Brooks, KF Fox, L Goncalves, P Kearney, L Michalis, ... European heart journal 41 (38), 3605-3692, 2020 | 56 | 2020 |
| Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK C Plummer, A Michael, G Shaikh, M Stewart, L Buckley, T Miles, ... British journal of cancer 121 (2), 109-116, 2019 | 56 | 2019 |
| A continuous patient activity monitor: validation and relation to disability DJ Walker, PS Heslop, CJ Plummer, T Essex, S Chandler Physiological Measurement 18 (1), 49, 1997 | 45 | 1997 |
| BSE and BCOS guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab R Dobson, AK Ghosh, B Ky, T Marwick, M Stout, A Harkness, R Steeds, ... Cardio Oncology 3 (1), 1-16, 2021 | 43 | 2021 |
| Cardiotoxicity in patients treated with bevacizumab is potentially reversible EA Hawkes, AFC Okines, C Plummer, D Cunningham Journal of Clinical Oncology 29 (18), e560-e562, 2011 | 43 | 2011 |
| A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia G Smith, J Apperley, D Milojkovic, NCP Cross, L Foroni, J Byrne, ... British Journal of Haematology 191 (2), 171-193, 2020 | 42 | 2020 |
| Trastuzumab-associated cardiac events in the Persephone trial HM Earl, AL Vallier, J Dunn, S Loi, E Ogburn, K McAdam, ... British journal of cancer 115 (12), 1462-1470, 2016 | 37 | 2016 |
| Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects … MJ Ehrhardt, JM Leerink, RL Mulder, A Mavinkurve-Groothuis, W Kok, ... The Lancet Oncology 24 (3), e108-e120, 2023 | 35 | 2023 |
| Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials E Agostinetto, D Eiger, M Lambertini, M Ceppi, M Bruzzone, N Pondé, ... European Journal of Cancer 148, 76-91, 2021 | 35 | 2021 |
| A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer S Halford, GJ Veal, SR Wedge, GS Payne, CM Bacon, P Sloan, I Dragoni, ... Clinical Cancer Research 29 (8), 1429-1439, 2023 | 33 | 2023 |
| Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: a systematic review and recommendations from the International Late Effects … EC van Dalen, RL Mulder, E Suh, MJ Ehrhardt, GJ Aune, E Bardi, ... European Journal of Cancer 156, 127-137, 2021 | 31 | 2021 |
| British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving … R Dobson, AK Ghosh, B Ky, T Marwick, M Stout, A Harkness, R Steeds, ... Echo Research & Practice 8 (1), G1-G18, 2021 | 23 | 2021 |
| Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting M Trojano, H Butzkueven, L Kappos, H Wiendl, T Spelman, F Pellegrini, ... Multiple sclerosis and related disorders 24, 11-19, 2018 | 20 | 2018 |
| Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. H Earl, L Hiller, AL Vallier, S Loi, K McAdam, L Hughes-Davies, D Rea, ... Health technology assessment (Winchester, England) 24 (40), 1, 2020 | 17 | 2020 |
| Using bevacizumab to treat metastatic cancer: UK consensus guidelines D Miles, J Bridgewater, P Ellis, M Harrison, P Nathan, M Nicolson, ... British Journal of Hospital Medicine 71 (12), 670-678, 2010 | 17 | 2010 |
